MedTrace Logo

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

NCT02538627 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-09-05

No results posted yet for this study

Summary

This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.

Conditions

Interventions

DRUG

MM-151

MM-151

DRUG

MM-121

MM-121

DRUG

MM-141

MM-141

DRUG

trametinib

trametininb

Sponsors & Collaborators

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-10-05
Completion
2016-10-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02538627 on ClinicalTrials.gov